Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $102.62 --0%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SUNE, NSLR, OCTV, More
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SUNE, NSLR, OCTV, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius soars on second quarter revenue beat
- SunEdison (SUNE) Misses Q2 EPS by 52c
- Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
